Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes.
Abstract
Chronic hyperglycaemia causes glycation which subsequently results in the long-term complications of diabetes. Albumin, the major plasma protein is more sensitive to glycation resulting in structural, biological and physiological modifications. The long-term benefits of commonly used anti-diabetic drugs such as metformin and glipizide in diabetic patients are well understood. However, no extensive study has been performed to assess their role in the glycation induced albumin modifications and cellular protection. We carried out the glycation of bovine serum albumin using methylglyoxal as a glycati...
Source: Molecular Biology Reports - February 13, 2016 Category: Molecular Biology Authors: Adeshara K, Tupe R Tags: Mol Biol Rep Source Type: research
Comparison of alogliptin and glipizide in composites of HbA1c reduction, no hypoglycaemia, and no weight gain in type 2 diabetes mellitus
Abstract
This was a post‐hoc analysis of a 2‐year, double‐blind study of 2639 patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy which assessed achievement of a composite endpoint of sustained HbA1c reduction (≤7.0% at Week 104 or ≥0.5% from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12.5 mg and 25 mg daily or glipizide (≤20 mg daily), each added to metformin
With an HbA1c target of ≤7.0%, 24.2% and 26.9% of patients treated with alogliptin 12.5 mg and 25 mg, respectively achieved the composite endpoint vs. 10.7% of patients treated wi...
Source: Diabetes, Obesity and Metabolism - February 10, 2016 Category: Endocrinology Authors: Stefano Del Prato, Penny Fleck, Craig Wilson, Paresh Chaudhari Tags: RESEARCH LETTER Source Type: research
Linezolid and Rasagiline - A culprit for serotonin syndrome
We present here a case of rare incidence of serotonin syndrome associated with linezolid and rasagiline. (Source: Indian Journal of Pharmacology)
Source: Indian Journal of Pharmacology - January 20, 2016 Category: Drugs & Pharmacology Authors: Mohamed HishamMundalipalayam N SivakumarV NandakumarS Lakshmikanthcharan Source Type: research
Development and validation of an LC–MS/MS sulfonylurea assay for hypoglycemia cases in the emergency department
Conclusion We have developed a rapid and sensitive LC–MS/MS sulfonylurea assay, and utilized this assay to assist in the differential diagnosis of unexplained hypoglycemia. (Source: Clinica Chimica Acta)
Source: Clinica Chimica Acta - January 17, 2016 Category: Laboratory Medicine Source Type: research
Efficacy and Safety of Berberine in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis
Conclusion BBR may have the beneficial effects in the control of blood glucose levels, though the efficacy of BBR is not superior to MET. BBR appeares to have advantages over rosiglitazone in improving FBG levels. In addition, the combination therapy of BBR and oral hypoglycemic agents may be a new attempt. However, the efficacy of BBR in patients with T2DM should be further evaluated by more RCTs in a larger population of patients. (Source: Chinese Herbal Medicines)
Source: Chinese Herbal Medicines - November 27, 2015 Category: Complementary Medicine Source Type: research
Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes.
CONCLUSIONS: Add-on therapy with pioglitazone may be more effective than glipizide for inhibiting platelet activation in T2DM.
PMID: 25855920 [PubMed - indexed for MEDLINE] (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - November 20, 2015 Category: Drugs & Pharmacology Authors: Xiao CC, Ren A, Yang J, Ye SD, Xing XN, Li SM, Chen C, Chen RP Tags: Eur Rev Med Pharmacol Sci Source Type: research
Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation
Conclusion: The moderate inhibition observed for clopidogrel bioactivation may not present a significant risk for drug-drug interactions between sulfonylureas and clopidogrel. While these findings bode well for multidrug therapies involving sulfonylureas and clopidogrel, clinical investigations are needed to define the clinical risk and benefit for combining these agents for the management of cardiovascular events in diabetic patients.Pharmacology 2016;97:18-24 (Source: Pharmacology)
Source: Pharmacology - November 17, 2015 Category: Drugs & Pharmacology Source Type: research
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
CONCLUSIONS: Concomitant therapy with a sulfonylurea and fibrate is associated with an often delayed increased rate of severe hypoglycemia. This article is protected by copyright. All rights reserved.
PMID: 26566262 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - November 13, 2015 Category: Drugs & Pharmacology Authors: Leonard CE, Bilker WB, Brensinger CM, Han X, Flory JH, Flockhart DA, Gagne JJ, Cardillo S, Hennessy S Tags: Clin Pharmacol Ther Source Type: research
Short ‐term and long‐term effects of dipeptidyl peptidase‐4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta‐analysis of randomized controlled trials
Summary
To assess the short‐term and long‐term effects of dipeptidyl peptidase‐4 (DPP‐4) inhibitors in type 2 diabetes mellitus patients with renal impairment, a meta‐analysis of randomized clinical trials of DPP‐4 inhibitor interventions in type 2 diabetes mellitus patients with renal impairment was performed. PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched through the end of March 2015. Randomized clinical trials were selected if (1) DPP‐4 inhibitors were compared with a placebo or other active‐comparators, (2) the treatment duration was ≥12 weeks and (3) data regarding changes in...
Source: Diabetes/Metabolism Research and Reviews - November 10, 2015 Category: Endocrinology Authors: Ruifei Li, Rui Wang, Haixia Li, Sihao Sun, Meijuan Zou, Gang Cheng Tags: Review Article Source Type: research
Cost of Achieving Combined Improvements in HbA1c and Weight without Hypoglycaemia over 4 Years in a Post-Hoc Analysis of Dapagliflozin + MET Vs Glipizide + MET
The SGLT2 inhibitor dapagliflozin (DAPA) increases glucosuria in an insulin-independent manner resulting in reductions in hyperglycemia, weight and BP with a low risk of hypoglycemia. Glipizide (GLIP) reduces hyperglycemia by increasing beta cell insulin secretion with risk of hypoglycaemia and weight gain. We conducted a cost analysis of treating patients over 4 years to two relevant composite endpoints: (1) HbA1c lowering of ≤0.5%, no major or minor hypoglycaemic events and weight loss ≥3% and (2) HbA1c lowering of ≤0.5%, no major or minor hypoglycaemic events and weight loss ≥5%. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: P Johansen, J Mukherjee, E Sörstadius, C Sternhufvud Source Type: research
Economics Analysis of Dapagliflozin Compare to Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus in Spain: Cost of Achieving Composite Endpoints
Evaluate the cost analysis of fix dose combination of dapagliflozin plus metformin (DAPA+MET) compared with glipizide plus metformin (SU+MET), in the treatment of type 2 diabetes mellitus during one year. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Capel, L Cordero Source Type: research
Recent Half-life of sulfonylureas in HNF1A and HNF4A human MODY patients is not prolonged as suggested by the mouse Hnf1a-/- model.
Conclusions We rejected the hypothesis that all human MODY-associated mutations in HNF1A / HNF4A induce changes in the pharmacokinetics of sulfonylureas in humans analogically to the Hnf1a-/- mouse model.
PMID: 26446475 [PubMed - as supplied by publisher] (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 8, 2015 Category: Drugs & Pharmacology Authors: Urbanová J, Anděl M, Potočková J, Klíma J, Macek J, Ptáček P, Ma'oška V, Kumštýřová T, Heneberg P Tags: Curr Pharm Des Source Type: research
Short‐term and long‐term effects of dipeptidyl peptidase‐4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta‐analysis of randomized controlled trials
ConclusionsThe present meta‐analysis confirms that DPP‐4 inhibitors are effective and equivalent to other agents in T2DM patients with RI. This article is protected by copyright. All rights reserved. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - October 3, 2015 Category: Endocrinology Authors: Ruifei Li, Rui Wang, Haixia Li, Sihao Sun, Meijuan Zou, Gang Cheng Tags: Review Article Source Type: research
Study of the Mucoadhesive Potential of Carbopol Polymer in the Preparation of Microbeads Containing the Antidiabetic Drug Glipizide.
Abstract
The present investigation was aimed at exploitation of the mucoadhesive potential of carbopol 934P polymer in developing microbeads of glipizide (GLP) for its effectivity in controlling blood sugar in diabetic patients. Various batches of GLP beads were prepared by an emulsion-solvent evaporation technique using the release-retarding polymer carbopol and subjected to a systematic evaluation such as physical characterization, ex vivo mucoadhesion, hydration and erosion test, and in vitro drug release; and instrumental and in vivo studies were performed with the best formulation. The highest yield a...
Source: AAPS PharmSciTech - September 4, 2015 Category: Drugs & Pharmacology Authors: Bera K, Mazumder B, Khanam J Tags: AAPS PharmSciTech Source Type: research
Utility of capillary microsampling for rat pharmacokinetic studies: Comparison of tail-vein bleed to jugular vein cannula sampling
In this report, five compounds were dosed orally into rats. For three proprietary compounds, jugular vein cannula (JVC) sampling was used to collect whole blood and plasma samples and capillary microsampling (CMS) was used to collect blood samples from the tail vein of the same animal. For the two other compounds, marketed drugs fluoxetine and glipizide, JVC sampling was used to collect both whole blood and blood CMS samples while tail-vein sampling from the same rats was also used to collect both whole blood and blood CMS samples. Results For the three proprietary compounds, the blood AUC as well as the blood concentrat...
Source: Journal of Pharmacological and Toxicological Methods - July 16, 2015 Category: Drugs & Pharmacology Source Type: research
